Drug intelligence / Profile preview

humadstrocel

Development stage: Preclinical
Lead developer: JangoBio
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intraarticular

Overview

Jango-Restore (humadstrocel) is a cell therapy candidate developed by JangoBio for the treatment of osteoarthritis. The therapy utilizes partially differentiated adipose-derived stem cells (ADSCs) to address joint degeneration and inflammation. By leveraging the regenerative properties of these stem cells, Jango-Restore aims to restore joint function and improve patient outcomes in human osteoarthritis. The program is currently in the preclinical stage of development and is being advanced by JangoMed, a subsidiary of JangoBio.

Brand names: Jango-Restore
Other names: humadstrocel

Beyond the preview

Go deeper on humadstrocel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on humadstrocel.

Explore the full profile